Dr. Blain is an internationally known expert in cell cycle and cancer biology, and is one of the world’s experts on p27Kip1. She has been studying cell cycle regulation for more than 25 years as an NIH funded investigator and tenured Associate Professor at the SUNY Downstate Medical Center. She founded Concarlo, capitalizing on discoveries she made and patented. She was trained at Princeton, Columbia and the Memorial Sloan-Kettering Cancer Center.

Mr. Mraz’s career has been focused in the financial markets for over 30 years since he joined JPMorgan in 1989. In 1999 he was a co-founding partner of the money management firm, Ospraie Management, where he is still an active partner today.In 2015 he teamed with Dr. Stacy Blain to found Concarlo and guides the team on all financial mattersIn 2017, he lead the development of the Ospraie AgScience team and platform, which currently invests in catalytic agricultural biotechnology.

Dr. Allamneni is a biopharma R&D expert with almost 20+ IND/IMPD submissions, 6 NDA/MAA approvals, and a track record of efficiently developing therapeutic candidates of various modalities. Forward-thinking leader in R&D strategy and tactical planning, and a highly regarded operational manager for key R&D functions. Impactful global regulatory interactions with FDA, MHRA, BfArM, ANSM, PMDA, Health Canada, TGA etc. during clinical development, partnership, and commercialization. Formerly with Turning Point, Jazz Pharmaceuticals and Genentech.

Dr. Bridon is an R&D executive with extensive North American and international experience of drug development from research to proof-of-concept clinical studies (Phase II) and regulatory submission in EU and US. 20+ years of experience with peptides therapeutics including drug protein bio-conjugate development across multiple therapeutic areas to treat cancer, anti-infective, metabolic and cardiovascular diseases. He previously held various management positions at Optivia (acquired by BioIVT), Ipsen, Abbott, Enobia (acquired by Alexion) and Neuronax and served on the scientific boards of Syntaxin (acquired by Ipsen) and Biosortia. He is currently CEO of Diaccurate, a Paris-based star-up.

Ms. Matz, RPh, is a seasoned, results oriented pharmaceutical professional providing technical consulting in the areas of product formulation and process development for preclinical through Phase 4 studies. Her expertise encompasses the preparation and manufacture of a myriad of delivery systems including tablets (IR, MR and ER, orally disintegrating and thin films), capsules (hard and soft shell), spray dried and dispersed systems, liquids (solutions, micro emulsions, suspensions and nasogastric enteral systems), transdermal drug delivery systems, topicals (ointments, creams and sticks), MDI’s, DPI’s, suppositories, etc. She also has extensive experience in conducting process scale-up and validation; clinical trial material and launch supply manufacturing and packaging; technology transfers; NDA/CTD writing, etc. She has worked with Pfizer, Medivation, Boehringer Ingelheim and Key Pharmaceuticals developing proprietary NME’s as well as having worked with generic companies. Furthermore, she is named on several patents.

Jeff Millard has both academic and industrial experience in chemistry and pharmaceutical sciences covering all aspects of CMC (chemistry, manufacturing, and controls). He has been directly responsible for the research and IND authoring of more than 7 IND submissions (to both CDER and CBER), IMPDs, and several successful SBIR grant applications. His drug product experience includes pre-formulation, formulation, tech transfer and cGMP manufacturing of both solid oral dosages as well as sterile, complex parenterals including liposomes.

Dr. DeVita is an experienced medicinal chemist and drug hunter in academia, biotech and large pharmaceutical environments. He has over 30 years of drug discovery and development experience including expertise managing multi-disciplinary teams to deliver on key program objectives for complex molecular targets. Dr. DeVita started his career at Merck Research Laboratories and rose to Director of Medicinal Chemistry, where he delivered many development candidates and led drug discovery and development teams. Dr. DeVita was also VP of Chemistry at Agios Pharmaceuticals focused on oncology drug discovery. Since 2013, he founded a consulting firm which has consulted for a wide variety of clients including biotechs building translational drug discovery programs. He is also Professor in the Dept. of Pharmacological Sciences and Director of Medicinal Chemistry in the Drug Discovery Institute of Icahn School of Medicine at Mt. Sinai since 2014.

Dr. Wu is an Associate Professor in the Department of Biomedical Engineering at University at Buffalo, The State University of New York (SUNY Buffalo). Her research focuses on the development of nanotherapeutics for cancer and chronic diseases and the development of in vitro diagnostic tests for cancer screening, diagnosis and prognosis. She received her Ph.D. from the Department of Chemical and Biomolecular Engineering at the Ohio State University in 2009. After completion of her degree, she received her postdoc training in the NSF Nanoscale Science and Engineering Center at the Ohio State University.

Sean Larkin has over a decade of experience in CFO / COO roles, spanning the startup process through corporate growth and change initiatives. His specialties include organizational management and emerging technologies. Prior to Concarlo Therapeutics, Sean was running outsourced CFO Firm LBC, LLC, working as a member of the Masotti & Masotti Digital Asset Group and as a member of MMBA, which is a blockchain education platform.

Maddie Whoriskey is a college student at Yale University who assists with administrative tasks at Concarlo.